segmental glomerulosclerosis (FSGS), which presents as severe podocyte injury and massive 23 proteinuria and has a poorly understood mechanism. The current study was designed to test the 24 hypothesis that the peroxisome proliferator-activated receptor-γ coactivator 1α 1α)/mitochondria axis is involved in ADR-induced podocyte injury. Using MPC5 immortalized 26 mouse podocytes, the ADR dose-dependently induced the downregulation of nephrin and 27 podocin, cell apoptosis, and mitochondrial dysfunction based on the increase in mitochondrial 28 reactive oxygen species (ROS) production, a decrease in mitochondrial DNA (mtDNA) copy 29 number, and the reduction of mitochondrial membrane potential (MMP) and ATP content. 30 Moreover, ADR treatment also remarkably reduced the expression of PGC-1α, an important 31 regulator of mitochondrial biogenesis and function, in podocytes. Strikingly, PGC-1α 32 overexpression markedly attenuated mitochondrial dysfunction, reduction of nephrin and 33 podocin, and the apoptotic response in podocytes following ADR treatment. Moreover, the 34 downregulation of PGC-1α and mitochondria disruption in podocytes were also observed in rat 35 kidneys with ADR administration, suggesting that the PGC-1α/mitochondria axis is relevant to
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Adriamycin is one of the most potent chemotherapeutic agents for treating many cancer 45 types in the clinic. However, the severe toxicity to noncancerous cells, particularly to cells in the 46 kidney and heart, has greatly limited its application. ADR-induced kidney injury, which is called 47 adriamycin nephropathy, is a severe clinical complication with high mortality and morbidity. In 48 rodents, ADR can induce glomerular injury with a pathology similar to focal segmental 49 glomerulosclerosis (FSGS), which is characterized by podocyte dysfunction, proteinuria, reduced 50 GFR, and tubulointerstitial fibrosis (22) . Although a number of studies on adriamycin 51 nephropathy have been performed in recent decades, the therapeutic outcome of this disease 52 remains unsatisfactory because of the uncertain pathogenesis and lack of specific therapeutic 53 targets. The podocyte has recently become a focus in this field, and there is growing evidence 54 that ADR is toxic for podocytes, which subsequently causes podocyte damage, FSGS 55 development, and proteinuria (10, 39). 56 In addition to being useful for studying the kidney side effects of ADR, the ADR-induced 57 nephropathy model mimics human FSGS. In the clinic, FSGS is a common pathological 58 manifestation of nephrotic syndrome in children and an important cause of renal failure in adults 59 (5, 12, 20). As a podocyte disease (28), FSGS has a poorly understood pathogenic mechanism 60 and unsatisfactory response to traditional therapies such as steroids and immunosuppressants ( maintained at 33°C with interferon-γ for proliferation, and they were cultured at 37°C in the 99 absence of interferon-γ to induce differentiation. All cells were between passages 3 and 5. In adverse conditions, the mitochondrial respiratory chain is one of the most prominent 259 sources of intracellular ROS production (7). In response to excess ROS, mitochondrial thiols are 260 rapidly oxidized, and the ADP and ATP exchange is impaired to the point that ATP synthase is 261 partially blocked (3, 33). In the present study, we detected a robust increase in mitochondria- 
